²²⁵Ac‑RAX104: A Next‑Generation PSMA Alpha Radioligand for Advanced Prostate Cancer
RAX104 is a small molecule ligand designed specifically to target PSMA, the protein that is highly expressed on the surface of prostate cancer cells. When labeled with ²²⁵Ac, it forms a radioligand that combines the physical advantages of actinium‑225 (high linear energy transfer and a 10‑day half‑life) with a ligand engineered for better tumor retention. […]
